TABLE 4.

Methylation differences of S100P and HYAL2 between BC cases and controls in Study II.

CpG sites	Controls median (IQR)	BC cases median (IQR)	OR (95% CI)* per −10% methylation	p-value*
S100P_CpG_2.3	0.63 (0.61–0.67)	0.62 (0.60–0.66)	1.38 (0.71–2.69)	0.348
S100P_CpG_4	0.71 (0.67–0.76)	0.68 (0.60–0.71)	1.90 (1.23–2.95)	0.004
S100P_CpG_7	0.45 (0.39–0.52)	0.41 (0.35–0.49)	1.54 (1.11–2.15)	0.011
S100P_CpG_8	0.46 (0.41–0.51)	0.44 (0.36–0.50)	1.64 (1.09–2.47)	0.017
S100P_CpG_9	0.55 (0.51–0.58)	0.54 (0.48–0.59)	1.66 (1.06–2.60)	0.028
S100P_CpG_10.11.12	0.62 (0.58–0.65)	0.59 (0.54–0.64)	1.87 (1.07–3.29)	0.029
HYAL2_CpG_1	0.32 (0.27–0.36)	0.29 (0.22–0.32)	2.49 (1.42–4.34)	0.001
HYAL2_CpG_2	0.22 (0.18–0.26)	0.21 (0.14–0.24)	1.61 (0.93–2.77)	0.086
HYAL2_CpG_3	0.36 (0.31–0.40)	0.34 (0.28–0.38)	1.97 (1.18–3.30)	0.009
HYAL2_CpG_4	0.54 (0.51–0.59)	0.52 (0.42–0.57)	2.04 (1.30–3.22)	0.002

*Logistic regression, adjusted for age and batches of measurement. BC, breast cancer; S100P, S100 calcium-binding protein P gene; HYAL2, hyaluronoglucosaminidase 2 gene; OR, odds ratio; IQR, interquartile range. The bold values indicate p < 0.05.